CMT Targets Cancer, Prenatal Testing Markets In China
This article was originally published in The Gray Sheet
Executive Summary
China Medical Technologies plans to exploit China's efforts to expand health care access by launching prenatal and postnatal tests as well as cancer diagnostics based on newly acquired fluorescent in situ hybridization technology
You may also be interested in...
China Medical Technologies Invests $345 Million In HPV Genotyping Chip
China Medical Technologies is acquiring a human papillomavirus genotyping assay which it expects will generate up to $26.5 million in sales next year
China Medical Technologies Invests $345 Million In HPV Genotyping Chip
China Medical Technologies is acquiring a human papillomavirus genotyping assay which it expects will generate up to $26.5 million in sales next year
Diagnostics in China
China Medical Technologies broadens its in vitro diagnostic market presence in China through the purchase of Beijing Bio-Ekon Biotechnology for $28.8 million, announced Nov. 26. The acquired firm offers enzyme-linked immunosorbent assays and semi-automatic, enhanced chemiluminescence immunoassay (ECLIA) analyzers and related reagents in China, and expects to seek approval in China next year for a fully automatic version. CMT, which also offers ECLIA products, acquired fluorescent in situ hybridization diagnostics technology in February (1"The Gray Sheet" Feb. 12, 2007, p. 8)